Abstract
Environmental pharmacology is the knowledge, study and the methods implemented for amalgamating the presence of pharmaceutical products and their metabolites in the environment. Pharmaceutical and house care products and their metabolites gain access to the environment through various means and affect the flora and fauna and modulate the ecosystem. The effect on wildlife, biofilms and human are being studied to gain knowledge of sources and causations. Potential risks of development of acute and chronic toxicity, carcinogenicity, interference with hormone and immune systems and drug resistance are of major concern. They may alter the genome and can affect future generations leaving them vulnerable to disease. There are regulations in good manufacturing practices and disposal which take into account the environmental risks but the knowledge for stakeholders and their implementation is very restricted. Ecopharmacology and ecopharmacovigilance are propagators of green healthcare. A strategy towards human health risk assessment and ecotoxicological hazard evaluation must be developed and risk minimization measures to be sought for and applied.
Research funding: Authors state no funding involved.
Conflict of interest: Authors state no conflict of interest.
Informed consent: Informed consent is not applicable.
Ethical approval: The conducted research is not related to either human or animal use.
References
1. Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, Rideout BA, et al. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 2004;427(6975):630–3.10.1038/nature02317Search in Google Scholar
2. Saenz VL, Booth W, Schal C, Vargo EL. Genetic analysis of bed bug populations reveals small propagule size within individual infestations but high genetic diversity across infestations from the eastern United States. J Med Entomol 2012;49(4): 865–75.10.1603/ME11202Search in Google Scholar
3. Harada M. Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Crit Rev Toxicol 1995;25(1):1–24.10.3109/10408449509089885Search in Google Scholar
4. Gluhovschi G, Margineanu F, Velciov S, Gluhovschi C, Bob F, Petrica L, et al. Fifty years of Balkan endemic nephropathy in Romania: some aspects of the endemic focus in the Mehedinti county. Clin Nephrol 2011;75(1):34–48.Search in Google Scholar
5. Heinrich M, Chan J, Wanke S, Neinhuis C, Simmonds MS. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2 – a global assessment based on bibliographic sources. J Ethnopharmacol 2009;125(1):108–44.10.1016/j.jep.2009.05.028Search in Google Scholar
6. Bound JP, Voulvoulis N. Pharmaceuticals in the aquatic environment – a comparison of risk assessment strategies. Chemosphere 2004;56(11):1143–55.10.1016/j.chemosphere.2004.05.010Search in Google Scholar
7. Jones OA, Voulvoulis N, Lester JN. Human pharmaceuticals in the aquatic environment a review. Environ Technol 2001;22(12):1383–94.10.1080/09593330.2001.11090873Search in Google Scholar
8. Cuklev F, Fick J, Cvijovic M, Kristiansson E, Forlin L, Larsson DG. Does ketoprofen or diclofenac pose the lowest risk to fish? J Hazard Mater 2012;229–230:100–6.10.1016/j.jhazmat.2012.05.077Search in Google Scholar
9. Shanmugam G, Sampath S, Selvaraj KK, Larsson DG, Ramaswamy BR. Non-steroidal anti-inflammatory drugs in Indian rivers. Environ Sci Pollut Res Int 2014;21(2):921–31.10.1007/s11356-013-1957-6Search in Google Scholar
10. Lawrence R, Jeyakumar E. Antimicrobial resistance: a cause for global concern. BMC Proc 2013;7(Suppl 3):S1.10.1186/1753-6561-7-S3-S1Search in Google Scholar
11. Rosenblatt-Farrell N. The landscape of antibiotic resistance. Environ Health Perspect 2009;117(6):A244–50.10.1289/ehp.117-a244Search in Google Scholar
12. Singer AC, Shaw H, Rhodes V, Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front Microbiol 2016;7:1728.10.3389/fmicb.2016.01728Search in Google Scholar
13. Govil PK, Sorlie JE, Murthy NN, Sujatha D, Reddy GL, Rudolph-Lund K, et al. Soil contamination of heavy metals in the Katedan Industrial Development Area, Hyderabad, India. Environ Monit Assess 2008;140(1–3):313–23.10.1007/s10661-007-9869-xSearch in Google Scholar
14. Impacts of pharmaceutical pollution on communities and environment in India: Nodea Asset Management by changing markets and ecostorm. 2016. Available from: https://www.nordea.com/Images/35-107206/impacts%201-20.pdf.Search in Google Scholar
15. Hyderabad’s Pharmaceutical Pollution Crisis: Nordea Asset Management; 2018 [cited 2018 21.11.18]. Available from: https://www.nordea.com/Images/33-275718/FULL_REPORT_HYDERABADs_PHARMACEUTICAL_POLLUTION_CRISIS_2018.pdf.Search in Google Scholar
16. Ruhoy IS, Daughton CG. Beyond the medicine cabinet: an analysis of where and why medications accumulate. Environ Int 2008;34(8):1157–69.10.1016/j.envint.2008.05.002Search in Google Scholar
17. Segura PA, Francois M, Gagnon C, Sauve S. Review of the occurrence of anti-infectives in contaminated wastewaters and natural and drinking waters. Environ Health Perspect 2009;117(5):675–84.10.1289/ehp.11776Search in Google Scholar
18. Daughton CG, Ruhoy IS. The afterlife of drugs and the role of pharmecovigilance. Drug Saf 2008;31(12):1069–82.10.2165/0002018-200831120-00004Search in Google Scholar
19. Diwan V, Tamhankar AJ, Khandal RK, Sen S, Aggarwal M, Marothi Y, et al. Antibiotics and antibiotic-resistant bacteria in waters associated with a hospital in Ujjain, India. BMC Public Health 2010;10:414.10.1186/1471-2458-10-414Search in Google Scholar
20. Halling-Sorensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lutzhoft HC, Jorgensen SE. Occurrence, fate and effects of pharmaceutical substances in the environment – a review. Chemosphere 1998;36(2):357–93.10.1016/S0045-6535(97)00354-8Search in Google Scholar
21. Conroy RM, Meegan ME, Joyce T, McGuigan K, Barnes J. Solar disinfection of water reduces diarrhoeal disease: an update. Arch Dis Child 1999;81(4):337–8.10.1136/adc.81.4.337Search in Google Scholar
22. Ferrari B, Paxeus N, Lo Giudice R, Pollio A, Garric J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol Environ Saf 2003;55(3):359–70.10.1016/S0147-6513(02)00082-9Search in Google Scholar
23. Drury B, Scott J, Rosi-Marshall EJ, Kelly JJ. Triclosan exposure increases triclosan resistance and influences taxonomic composition of benthic bacterial communities. Environ Sci Technol 2013;47(15):8923–30.10.1021/es401919kSearch in Google Scholar
24. Wong MK, Tan P, Wee YC. Heavy metals in some Chinese herbal plants. Biol Trace Elem Res 1993;36(2):135–42.10.1007/BF02783172Search in Google Scholar
25. Ancion PY, Lear G, Dopheide A, Lewis GD. Metal concentrations in stream biofilm and sediments and their potential to explain biofilm microbial community structure. Environ Pollut 2013;173:117–24.10.1016/j.envpol.2012.10.012Search in Google Scholar
26. Karatan E, Watnick P. Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol Mol Biol Rev 2009;73(2):310–47.10.1128/MMBR.00041-08Search in Google Scholar
27. Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005;436(7054):1171–5.10.1038/nature03912Search in Google Scholar
28. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358(9276):135–8.10.1016/S0140-6736(01)05321-1Search in Google Scholar
29. Murga R, Forster TS, Brown E, Pruckler JM, Fields BS, Donlan RM. Role of biofilms in the survival of Legionella pneumophila in a model potable-water system. Microbiology 2001;147(Pt 11):3121–6.10.1099/00221287-147-11-3121Search in Google Scholar
30. Cleuvers M. Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol Lett 2003;142(3):185–94.10.1016/S0378-4274(03)00068-7Search in Google Scholar
31. Fent K, Weston AA, Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006;76(2):122–59.10.1016/j.aquatox.2005.09.009Search in Google Scholar
32. Genuis SJ, Schwalfenberg G, Siy AK, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One 2012;7(11):e49676.10.1371/journal.pone.0049676Search in Google Scholar
33. Archer E, Petrie B, Kasprzyk-Hordern B, Wolfaardt GM. The fate of pharmaceuticals and personal care products (PPCPs), endocrine disrupting contaminants (EDCs), metabolites and illicit drugs in a WWTW and environmental waters. Chemosphere 2017;174:437–46.10.1016/j.chemosphere.2017.01.101Search in Google Scholar
34. Fabbri E. Pharmaceuticals in the environment: expected and unexpected effects on aquatic fauna. Ann N Y Acad Sci 2015;1340:20–8.10.1111/nyas.12605Search in Google Scholar
35. Le Page Y, Vosges M, Servili A, Brion F, Kah O. Neuroendocrine effects of endocrine disruptors in teleost fish. J Toxicol Environ Health B Crit Rev 2011;14(5–7):370–86.10.1080/10937404.2011.578558Search in Google Scholar
36. Hotchkiss AK, Rider CV, Blystone CR, Wilson VS, Hartig PC, Ankley GT, et al. Fifteen years after “Wingspread” – environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go. Toxicol Sci 2008;105(2):235–59.10.1093/toxsci/kfn030Search in Google Scholar
37. Meeker JD. Exposure to environmental endocrine disruptors and child development. Arch Pediatr Adolesc Med 2012;166(6):E1–7.10.1001/archpediatrics.2012.241Search in Google Scholar
38. Hollander D. Environmental effects on reproductive health: the endocrine disruption hypothesis. Fam Plann Perspect 1997;29(2):82–6, 9.10.2307/2953367Search in Google Scholar
39. Ruiu L. Insect pathogenic bacteria in integrated pest management. Insects 2015;6(2):352–67.10.3390/insects6020352Search in Google Scholar
40. Chandler D, Bailey AS, Tatchell GM, Davidson G, Greaves J, Grant WP. The development, regulation and use of biopesticides for integrated pest management. Philos Trans R Soc Lond B Biol Sci 2011;366(1573):1987–98.10.1098/rstb.2010.0390Search in Google Scholar
41. Siefert JL. Defining the mobilome. Methods Mol Biol 2009;532:13–27.10.1007/978-1-60327-853-9_2Search in Google Scholar
42. Holm G, Snape JR, Murray-Smith R, Talbot J, Taylor D, Sorme P. Implementing ecopharmacovigilance in practice: challenges and potential opportunities. Drug Saf 2013;36:533–46.10.1007/s40264-013-0049-3Search in Google Scholar
43. Joakim Larsson DG, Fick J. Transparency throughout the production chain – a way to reduce pollution from the manufacturing of pharmaceuticals? Regul Toxicol Pharmacol 2009;53(3):161–3.10.1016/j.yrtph.2009.01.008Search in Google Scholar
44. European Union 2013 Directive 2013/39/EU of the European Parliament and of the Council of 12 August 2013 amending Directives 2000/60/EC and 2008/105/EC as regards priority substances in the field of water policy. Official Journal of the European Union L226; 2013. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2013:2226:0001:0017:EN:PDF.Search in Google Scholar
45. Finley RL, Collignon P, Larsson DG, McEwen SA, Li XZ, Gaze WH, et al. The scourge of antibiotic resistance: the important role of the environment. Clin Infect Dis 2013;57(5):704–10.10.1093/cid/cit355Search in Google Scholar
46. European Medical Agency 2006 Guideline on the environmental risk assessment of medicinal products for human use; 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003978.pdf.Search in Google Scholar
47. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 1998 Environmental Assessment of Human Drug and Biologics Applications; 1998. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070561.pdf.Search in Google Scholar
48. Pruden A, Larsson DG, Amezquita A, Collignon P, Brandt KK, Graham DW, et al. Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment. Environ Health Perspect 2013;121(8):878–85.10.1289/ehp.1206446Search in Google Scholar
49. 12 Design principles of Green Chemistry; 1998. Available from: https://www.acs.org/content/acs/en/greenchemistry/principles/12-principles-of-green-chemistry.html.Search in Google Scholar
50. Haricharan Raju CM, Naga Lakshmi P, Srinivas C, Reddy GO, Acharyulu PVR. A green chemistry approach to ibuprofen piconol. Synth Commun 2005;35(2):209–212.10.1081/SCC-200048418Search in Google Scholar
51. Fick J, Lindberg RH, Tysklind M, Larsson DG. Predicted critical environmental concentrations for 500 pharmaceuticals. Regul Toxicol Pharmacol 2010;58(3):516–23.10.1016/j.yrtph.2010.08.025Search in Google Scholar
52. Kummerer K, Velo G. Ecopharmacology: a new topic of importance in pharmacovigilance. Drug Saf 2006;29(5):371–3.10.2165/00002018-200629050-00001Search in Google Scholar
53. Baker DR, Kasprzyk-Hordern B. Spatial and temporal occurrence of pharmaceuticals and illicit drugs in the aqueous environment and during wastewater treatment: new developments. Sci Total Environ 2013;454–455:442–56.10.1016/j.scitotenv.2013.03.043Search in Google Scholar
54. Burns EE, Thomas-Oates J, Kolpin DW, Furlong ET, Boxall ABA. Are exposure predictions, used for the prioritization of pharmaceuticals in the environment, fit for purpose? Environ Toxicol Chem 2017;36(10):2823–32.10.1002/etc.3842Search in Google Scholar
55. Larsson DG. Pollution from drug manufacturing: review and perspectives. Philos Trans R Soc Lond B Biol Sci 2014;369(1656). doi: 10.1098/rstb.2013.0571.10.1098/rstb.2013.0571Search in Google Scholar
56. Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, et al. Risk management frameworks for human health and environmental risks. J Toxicol Environ Health B Crit Rev 2003;6(6):569–720.10.1080/10937400390208608Search in Google Scholar
57. Awe EO, Banjoko SO. Biochemical and haematological assessment of toxic effects of the leaf ethanol extract of Petroselinum crispum (Mill) Nyman ex A.W. Hill (Parsley) in rats. BMC Complement Altern Med 2013;13:75.10.1186/1472-6882-13-75Search in Google Scholar
58. Velo G. Erice Statement 2009: communication, medicines and patient safety. Br J Clin Pharmacol 2010;69(2):207–8.10.1111/j.1365-2125.2009.03562.xSearch in Google Scholar
59. Kuhler TC, Andersson M, Carlin G, Johnsson A, Akerblom L. Do biological medicinal products pose a risk to the environment?: a current view on ecopharmacovigilance. Drug Saf 2009;32(11):995–1000.10.2165/11316540-000000000-00000Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston
